Rare genetic mutation ‘could help stave off early-onset Alzheimer’s’
Researchers found the ‘Christchurch’ gene to have a protective effect in people who are at very high risk of developing the disease.
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.A rare gene mutation could hold the key to slowing down or even preventing early-onset Alzheimer’s, scientists believe, after they found the variant had a “protective” effect on people destined to develop the disease.
Researchers discovered that having one copy of the “Christchurch” gene meant these high-risk people showed signs of dementia four years later than those who did not carry the variant.
The team said the findings, published in the New England Journal Of Medicine, could pave the way for innovative treatments and targeted therapies for a disease that affects 982,000 people in the UK.
Dr Joseph F Arboleda-Velasquez, an associate scientist at Mass Eye and Ear teaching hospital in the US, said: “Our new study is significant because it increases our confidence that this target is not only protective, but druggable.
I am highly encouraged by our findings, as they suggest the potential for delaying cognitive decline and dementia in older individuals
“We think that therapeutics inspired by protected humans are much more likely to work and to be safer.”
The protective effect of the Christchurch gene was first reported in 2019 when scientists found a Colombian woman was able to stave off Alzheimer’s until her late 70s despite the disease running in her family.
Aliria Rosa Piedrahita de Villegas and many of her family members carry the “Paisa” gene mutation, which causes Alzheimer’s – with memory and thinking problems developing around the mid-40s.
But she was also found to carry two copies of the Christchurch gene, which meant the disease did not progress until she was well into her 70s.
Now researchers have found 27 other family members who carry both the Paisa mutation and one copy of the Christchurch variant also experienced delayed Alzheimer’s symptoms but this was less pronounced – with signs of impairment starting around the age 52.
Yakeel T Quiroz, associate professor in the Departments of Psychiatry and Neurology at Massachusetts General Hospital, said: “As a clinician, I am highly encouraged by our findings, as they suggest the potential for delaying cognitive decline and dementia in older individuals.
“Now we must leverage this new knowledge to develop effective treatments for dementia prevention.”
An international team of scientists led by Francisco Lopera at the University of Antioquia in Medellin, Colombia, have been studying Aliria’s extended family for around four decades in the hope of finding a cure for dementia, which affects 55 million worldwide.
The family consists of about 6,000 blood relatives, and about 1,200 carry the Paisa variant.
Prof Quiroz said: “As a next step, we are currently focused on improving our understanding of the brain resilience among the remaining family members who carry one copy of the Christchurch variant.
“This involves conducting structural and functional MRI scans and cognitive evaluations, as well as analysing blood samples to assess their protein and biomarker profiles.”